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Abstract
Background: Advances in treatment of acute lymphocytic leukemia increased the likelihood of developing late
treatment-associated effects, such as abdominal adiposity, increasing the risk of cardiovascular disease in this
population. Cranial radiotherapy is one of the factors that might be involved in this process. The aim of this study
was to determine the effect of cranial radiotherapy on adiposity indexes in survivors of acute lymphocytic leukemia.
Methods: A comparative cross-sectional study of 56 acute lymphocytic leukemia survivors, chronological age
between 15 and 24 years, assigned into two groups according to the exposure to cranial radiotherapy (25 irradiated
and 31 non-irradiated), assessed according to body fat (dual energy X-ray absorptiometry), computed tomography
scan-derived abdominal adipose tissue, lipid profile, and insulin resistance.
Results: Cranial radiotherapy increased body fat and abdominal adipose tissue and altered lipid panel. Yet, lipids
showed no clinical relevance so far. There were significantly more obese patients among those who received
cranial radiotherapy (52% irradiated versus 22.6% non-irradiated), based on dual energy X-ray absorptiometry body
fat measurements. Nonetheless, no association was observed between cranial radiotherapy and body mass index,
waist circumference, waist-to-height ratio or insulin resistance.
Conclusions: Adolescent and young adult survivors of childhood acute lymphocytic leukemia showed an increase
in body fat and an alteration of fat distribution, which were related to cranial radiotherapy. Fat compartment
modifications possibly indicate a disease of adipose tissue, and cranial radiotherapy imports in this process.
Keywords: Precursor cell lymphoblastic leukemia-lymphoma/radiotherapy, Adiposity, Abdominal fat, Lipid
metabolism disorders, Insulin resistance
Background
Acute lymphocytic leukemia (ALL) is the most prevalent
cancer in children and accounts for 80% of childhood
leukemia [1]. In the past 20 years, survival rates have
markedly increased with advances in treatment, and a
significant number of late effects, secondary to therapy,
such as weight gain, growth retardation and metabolic
syndrome, have emerged [2-6].
Various mechanisms of weight gain have been reported
in this group of patients, including premature adiposity
rebound, growth hormone deficiency, leptin insensitivity
and other factors related to lifestyle and genetics [2,4,7,8].
Nonetheless, some studies have not characterized obesity
by means of body mass index (BMI) in ALL survivors,
despite exposure to cranial radiotherapy (CRT) [8,9], even
though an increase in BMI has often been described in
this group of patients [2-4,6].
In addition to BMI, which is an established and useful
marker of adiposity, a more detailed evaluation of body
fat regional distribution is desired. Specifically, an excess
accumulation of visceral fat within the abdomen is
strongly and independently associated with cardiovascu-
lar morbidity and mortality in general population [10].
CRT has been identified as a possible factor contributing
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to modifications in body composition among ALL survi-
vors [2,3,6,11,12]. To date, a more meticulous analysis of
adiposity is essential because alterations in fat distribu-
tion might represent a causal link between ALL and
premature cardiovascular disease, which has been previ-
ously documented in this group of patients, particularly
those who received CRT [13,14].
Therefore, the purpose of this study was to assess the
impact of CRT on overall adiposity and body fat distri-
bution in young survivors of childhood ALL. Alterna-




This was a comparative cross-sectional study of a ran-
domly selected sampling of ALL survivors of both genders
from the Pediatric Oncology Institute (Federal University
of Sao Paulo, Brazil), admitted from May 1991 to June
2003. The study was approved by the Ethics Research
Committee of Federal University of Sao Paulo (No. 1197/
07). To participate in this study, patients or parents, when
appropriate, signed an informed consent form.
ALL subjects completed the Brazilian Cooperative
Group for Treatment of Childhood Acute Lymphocytic
Leukemia (GBTLI) international protocol. Details com-
prising drugs and CRT can be read elsewhere [15,16].
CRT was applied prophylactically to those at high risk
for relapse, defined accordingly to the recommendations
of the GBTLI, and/or therapeutically to those with cen-
tral nervous system involvement, defined as blast cells
greater than 5% in cerebrospinal fluid [15,16].
The inclusion criteria comprised chronological age be-
tween 15 and 24 years, the complete clinical remission
of ALL (complete absence of the disease in bone marrow
and blood), no ALL therapy for at least two years,
complete pubertal development (menarche in girls and
Tanner stage IV or above in boys) [17,18], growth of less
than 1 cm/year, bone age with full epiphyseal plate
fusion, normal renal, thyroid, gonadal and adrenal pro-
files (spontaneous or under hormonal replacement ther-
apy), and insulin-like growth factor-1 within the normal
limits. Patients who used anorexigens, insulin-sensitivity
medications or other drugs that interfere with adiposity
(e.g., metformin, sibutramine, and fluoxetine); who had
experienced exogenous growth hormone administration
within two years prior to study enrollment or a bone
marrow transplantation; and who were pregnant, were
postpartum, or had Down’s syndrome were excluded
from the study.
Survivors were stratified into two groups according to
the exposure to CRT (Yes or No). Characteristics of
host/disease and therapy were assessed from clinical ex-
aminations and/or medical records, encompassing: sex,
year of the GBTLI protocol employed, age at ALL
diagnosis, age at assessment, age and dose of CRT (if
employed), time since CRT, time post therapy, BMI Z
score at ALL diagnosis, medications or eventful past
medical history.
Variables
Adiposity indexes and metabolic profile were assessed in
ALL survivors at least 2 years post therapy. The BMI Z
score was evaluated at different moments of therapy:
diagnosis, treatment end, 2 years post treatment (period
of adiposity rebound), and current.
Adiposity indexes
Body composition variables
BMI and fat mass index (FMI). BMI was calculated as
the weight in kilograms divided by height in meters
squared (kg/m2) analysed in absolute values and/or
converted into Z scores, based on the National Center
for Health Statistics 2000 Centers for Disease Control
and Prevention growth curve charts [19]. Overweight
and obesity were defined as a BMI (absolute values)
above 25 and 30 kg/m2, respectively, or a BMI Z score
above 1.0 standard deviation (SD) and 2.0 SD, respect-
ively [19,20].
The body fat mass was assessed using dual energy X-ray
absorptiometry equipment (DXA), Hologic Discovery
4500 (QDR-4500A; Hologic Inc., Bedford, MA, USA),
according to a method described elsewhere [21]. The FMI
was calculated as the fat mass (in kilograms) divided by
height in meters squared (kg/m2). Total body fat (in per-
centage) above the 95th percentile was defined as obesity
in patients under 18 years of age [22], and cut-offs based
on the National Health and Evaluation Survey were used
for patients at or above 18 years old (35.2% and 30.3% for
females and males, respectively) [23].
Fat distribution indexes
Waist circumference (WC), hip circumference (HC),
waist-to-hip ratio, waist-to-height ratio and abdominal
adipose tissue, encompassing total adipose tissue (TAT)
and its two layers: visceral adipose tissue (VAT) and sub-
cutaneous adipose tissue (SAT). WC and HC were mea-
sured according to the methods described elsewhere
[24], and the ratios between WC and HC and WC and
height were defined as the waist-to-hip ratio and the
waist-to-height ratio, respectively.
The following WC cut-offs were considered for adults:
males larger than 102 cm and females larger than 88 cm
(above 19 years of age) on the basis of the National
Cholesterol Education Program - Adult Treatment Panel
III [25]; males at or above 94 cm and females at or above
80 cm (more than 16 years of age) according to the
International Diabetes Federation [26]. The cut-offs were
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modified for adolescents as follows: WC at or above the
90th percentile (at or below 19 years of age) according to
the National Cholesterol Education Program - Adult Treat-
ment Panel III (Cook et al. study) [27] and WC greater
than the 90th percentile (at or below 16 years of age)
according to the International Diabetes Federation [28].
Data by Freedman et al. (1999) from the Bogalusa Study
[29] were used to generate the WC percentiles. A waist-to
-height ratio above 0.5 indicated visceral adiposity [30].
The abdominal adipose tissue was evaluated using ab-
dominal computed tomography (CT) scans during the
morning hours. The CT scan was performed using a
Philips MX 8000 Dual, and the parameters for investiga-
tion were 120 kV, 150 mA, 3.24 s exposure time, and a
5 mm width measurement with the patient in a supine
position with the arms positioned beside the head. An
assortment of five axial images was obtained at the L4-L5
level. The volume of the TAT was calculated (in cm3)
with a computerized system of tridimensional analysis.
The VAT was determined after the delineation of the ab-
dominal cavity, including retroperitoneal, omental and
mesenteric adipose tissue. The SAT was obtained by the
difference between the TAT and VAT. The ratio between
the VAT and SAT was also obtained.
Metabolic profile
Blood samples were collected after a 12-hour overnight
fast, to assess the metabolic profile by measuring lipid
panel, glucose, and insulin.
Lipid panel
Total cholesterol, high-density lipoprotein (HDL) choles-
terol, and triglycerides were determined using a colorimetric
enzymatic method. Low-density lipoprotein (LDL) choles-
terol was calculated by the formula described by Friedewald
et al. (1972) [31]. Concerning HDL cholesterol and trigly-
ceride levels, the following cut-offs were considered as
dyslipidemia: HDL cholesterol < 1.0 mmol/L (< 40 mg/dL)
and triglycerides > 2.3 mmol/L (> 200 mg/dL) [32].
Glucose, insulin and insulin resistance
Fasting glucose was assayed using an automated method
and insulin levels in duplicate using ACTIVEW Insulin
ELISA DSL-10-1600, Diagnostics Systems Laboratories,
Inc., Webster, Texas, USA, having an intra- and inter-
assay coefficient of variability of 2% and 5%, respectively,
minimum detection limit of 1.8 pmol/L (0.3 μIU/mL),
and specificity of 100%. Altered glycemia was defined
according to Genuth et al. [33]. To establish insulin sen-
sitivity, glucose and insulin levels were determined to
calculate the homeostatic model assessment - insulin re-
sistance (HOMA1-IR) [34]. With the aim of defining
insulin resistance, a HOMA1-IR > 2.7 was assigned as
the cut-off [35].
Convertion factors to système international (SI)
Total cholesterol (1 mg/dL = 0.0259 mmol/L); LDL chol-
esterol (1 mg/dL = 0.0259 mmol/L); HDL cholesterol
(1 mg/dL = 0.0259 mmol/L); triglycerides (1 mg/dL =
0.0113 mmol/L); glucose (1 mg/dL = 0.0555 mmol/L)
and insulin (1 μIU/mL = 6.945 pmol/L).
Statistical analysis
Means and SDs were used to summarize the numerical
variables and frequency counts and percentages to de-
scribe the categorical variables of the sampled subjects’
characteristics, according to CRT exposure. Fisher’s exact
test was used to compare the distribution of the categor-
ical variables between CRT levels. T-tests for independent
samples were used to compare the means of continuous
variables between CRT levels.
The relationship between the body composition, fat dis-
tribution and metabolic profile variables and CRT treat-
ment was evaluated through linear regression models.
Initially, regression models having body composition, fat
distribution and metabolic profile as dependent variables;
and exposure to CRT, sex and the interaction of CRT and
sex as independent variables were evaluated. If the inter-
action term was significant, CRT effect was evaluated
according to sex. If the interaction term was not statisti-
cally significant, it was removed from the model and the
main effects of sex and CRT were tested. Similarly, if sex
was not significant, it was removed from the model and
CRT main effect tested. If sex was significant, the main
effect of CRT adjusted for sex was reported.
A general multivariate linear model was used to com-
pare the BMI Z score profiles along different moments
of ALL therapy (diagnosis, treatment end, 2 years post
therapy and current) between CRT levels. This analysis
included an adjustment for age at diagnosis, which was
centered at 7.5 years.
The significance level was set at 0.050. The statistical




The sample comprised 56 ALL survivors aged [mean
(SD)] 18.6 (2.5) years who were 7.5 (3.9) years of age at
ALL diagnosis and 8.5 (3.5) years post therapy. The ALL
subjects completed the GBTLI international protocol, as
described in Table 1. Males encompassed 42.9% of the
population and 44.6% of the ALL survivors received
CRT treatment with a dose of either 18 Gy (76%) or
24 Gy (24%) at a mean age of 8.0 (4.0) years. ALL sub-
jects exposed to CRT were older at study assessment
while compared to those not exposed (T-test, p = 0.034).
Three subjects also received alternative protocols to
the GBTLI, which were employed due to medullar or
Siviero-Miachon et al. Radiation Oncology 2013, 8:39 Page 3 of 9
http://www.ro-journal.com/content/8/1/39
testicular relapses but without complementary CRT.
Among the irradiated survivors, one subject also re-
ceived spinal irradiation, and two patients received tes-
ticular radiotherapy (24 Gy). See Table 1 for further data.
Body composition
Regression models showed that a higher FMI was associ-
ated with CRT (mean difference [yes-no] = 2.14, p = 0.005)
(Table 2).
At ALL diagnosis, BMI Z score was not different as
regards CRT treatment (T-test, p = 0.055) and there was
no difference in overweight or obesity concerning expos-
ure to CRT (Fisher’s exact test, p = 0.862) (Table 1). A
general multivariate linear model adjusted for age at
diagnosis showed that there was a significant increase in
the BMI Z score profiles along different moments of
ALL therapy (diagnosis, treatment end, 2 years post
therapy and current) (all mean differences p < 0.050),
with no relation to the exposure to CRT (mean differ-
ence [yes-no] = 0.44, p = 0.080). For further data see Table 3
and Figure 1.
On account of the total body fat measurements (by
DXA), there were currently more obese patients among
the survivors exposed to CRT (52% exposed to CRT
versus 22.6% not exposed to CRT) (Fisher’s exact test,
p = 0.020). On the basis of BMI Z score, two males were
presently considered obese (3.6% of the ALL subjects and
8.3% of the male ALL subjects), and they were similarly
overweight at ALL diagnosis and 2 years post therapy.
There was no difference in overweight or obesity (through
BMI) along different moments of ALL therapy concerning
CRT treatment (Fisher’s exact test, p > 0.100).
Fat distribution
Treatment with CRT had an effect on all of the variables
derived from the CT scan: TAT (mean difference [yes-no]
= 206.91, p = 0.005), VAT (mean difference [yes-no] =
46.42, p = 0.006) and SAT (mean difference [yes-no] =
160.49, p = 0.009) (Table 2).
There was no difference between the CRT groups
with respect to abdominal obesity according to the
criteria of the National Cholesterol Education Pro-
gram - Adult Treatment Panel III, Cook et al. or the
International Diabetes Federation (Fisher’s exact test,
p > 0.100). Similarly, CRT did not influence WC, HC
or the waist-to-height ratio in a regression analysis
(Table 2).
Table 1 Subjects’ characteristics from 56 survivors of childhood ALL, according to CRT treatment
Total Exposure to CRT p value
No Yes
(n = 56) (n = 31) (n = 25)
Variable Count % Count % Count % Fisher’s exact test
Sex 0.590
Male 24 42.9 12 38.7 12 48.0
Female 32 57.1 19 61.3 13 52.0
GBTLI protocol 0.055
-85 9 16.1 3 9.7 6 24.0
-93 35 62.5 18 58.1 17 68.0
-99 12 21.4 10 32.2 2 8.0
BMI Z score at ALL diagnosis 0.862
Normal 46 82.1 26 83.9 20 80.0
Overweight 6 10.7 3 9.7 3 12.0
Obese 1 1.8 0 0.0 1 4.0
NA 3 5.4 2 6.4 1 4.0
Variable Mean SD Min Max Mean SD Min Max Mean SD Min Max T-test
Age at ALL diagnosis (years) 7.5 3.9 2.1 17.0 7.4 4.0 2.1 17.0 7.5 3.8 2.3 13.8 0.958
Age at assessment (years) 18.6 2.5 15.0 22.9 18.0 2.5 15.0 22.9 19.4 2.3 15.0 22.8 0.034
Age at CRT (years) 8.0 4.0 2.6 14.4 .. .. .. .. 8.0 4.0 2.6 14.4 ..
Time post therapy (years) 8.5 3.5 2.5 16.4 8.1 3.5 2.5 14.9 9.0 3.4 2.6 16.4 0.350
Time since CRT (years) 11.4 3.8 4.0 18.7 .. .. .. .. 11.4 3.8 4.0 18.7 ..
BMI Z score at ALL diagnosis -0.28 1.38 -5.39 2.44 -0.61 1.44 -5.39 1.19 0.12 1.22 -2.30 2.44 0.055
ALL Acute lymphocytic leukemia, CRT Cranial radiotherapy, GBTLI Brazilian Cooperative Group for Treatment of Childhood Acute Lymphocytic Leukemia, BMI Body
mass index, NA Not available, SD Standard deviation, Min Minimum, Max Maximum.
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Metabolic profile
Exposure to CRT increased total cholesterol (mean dif-
ference [yes-no] = 0.65, p = 0.010) and LDL cholesterol
(mean difference [yes-no] = 0.57, p = 0.003). CRT did not
influence HDL cholesterol, triglycerides or HOMA1-IR
in a regression analysis (Table 2).
No patient was considered glucose intolerant or dia-
betic. There was no association between dyslipidemia or
insulin resistance, and exposure to CRT (Fisher’s exact
test, p > 0.100).
Discussion
This study investigated whether a history of CRT, deliv-
ered as part of a complex ALL treatment, is associated
with increased adiposity or adipose tissue distribution in
ALL survivors. The major finding of this study is that
the group exposed to CRT showed increased body fat
and accelerated accumulation of fat in both layers of the
abdominal region, VAT and SAT, as well as altered lipid
panel. This difference in body fat and fat distribution in-
dexes could be attributed to the disease versus therapy,
Table 2 Effect of CRT on adiposity indexes and metabolic profile in 56 survivors of childhood ALL
Exposure to CRT Effect of CRT
Total No Yes
(n = 56) (n = 31) (n = 25)
Variable Mean (SD) Mean (SD) Mean (SD) Mean difference (Yes – No) SE 95%CI p
BMI (kg/m2) 22.7 (4.3) 21.7 (3.4) 23.8 (4.9) 2.13 1.12 [-0.12; 4.38] 0.063
BMI (Z score) 0.07 (1.17) -0.09 (1.20) 0.27 (1.12) 0.35 0.31 [-0.28; 0.98] 0.266
FMI (kg/m2) 6.7 (3.1) 5.8 (2.8) 7.7 (3.3) 2.14 0.73 [0.67; 3.61] 0.005
WC (cm) 81.1 (12.2) 78.9 (10.2) 83.8 (14.1) 4.80 3.25 [-1.71; 11.31] 0.145
HC (cm) 94.1 (8.0) 92.9 (7.6) 95.5 (8.4) 2.48 2.14 [-1.81; 6.78] 0.251
Waist-to-hip ratio 0.86 (0.08) 0.85 (0.07) 0.87 (0.10) 0.02 0.02 [-0.02; 0.06] 0.335
Waist-to-height ratio 0.50 (0.07) 0.48 (0.06) 0.52 (0.09) 0.04 0.02 [0.00; 0.08] 0.065
TAT (cm3) 467.0 (279.4) 374.6 (212.0) 581.5 (313.1) 206.91 70.38 [65.81; 348.01] 0.005
VAT (cm3) 109.6 (64.1) 88.8 (52.6) 135.3 (68.7) 46.42 16.21 [13.92; 78.91] 0.006
SAT (cm3) 357.4 (231.2) 285.8 (177.6) 446.3 (261.2) 160.49 58.80 [42.60; 278.38] 0.009
VAT/SAT 0.40 (0.30) 0.41 (0.34) 0.37 (0.25) -0.07 0.07 [-0.21; 0.08] 0.351
Total cholesterol (mmol/L) 3.9 (0.9) 3.6 (0.8) 4.3 (1.0) 0.65 0.24 [0.16; 1.13] 0.010
LDL cholesterol (mmol/L) 2.2 (0.7) 2.0 (0.6) 2.6 (0.7) 0.57 0.18 [0.21; 0.93] 0.003
HDL cholesterol (mmol/L) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 0.02 0.08 [-0.13; 0.18] 0.754
Triglycerides (mmol/L) 1.0 (0.5) 1.0 (0.5) 1.1 (0.5) 0.14 0.14 [-0.14; 0.42] 0.313
Glucose (mmol/L) 4.7 (0.4) 4.6 (0.3) 4.8 (0.4) 0.12 0.10 [-0.08; 0.31] 0.231
Insulin (pmol/L) 65.7 (30.8) 61.5 (27.5) 70.8 (34.2) 9.30 8.25 [-7.25; 25.84] 0.265
HOMA1-IR 2.01 (1.04) 1.85 (0.92) 2.20 (1.16) 0.34 0.28 [-0.21; 0.90] 0.221
CRT Cranial radiotherapy, ALL Acute lymphocytic leukemia, SD Standard deviation, SE Standard error, CI Confidence interval, BMI Body mass index, FMI Fat mass
index, WC Waist circumference, HC Hip circumference, TAT Total adipose tissue, VAT Visceral adipose tissue, SAT Subcutaneous adipose tissue, LDL Low-density
lipoprotein, HDL High-density lipoprotein, HOMA1-IR Homeostatic model assessment - insulin resistance.
Table 3 Comparison of BMI Z score from 56 survivors of childhood ALL along different moments of therapy
BMI (Z score) Mean Difference SE 95%CI p
CRT comparison
Yes - No 0.44 0.25 [-0.05; 0.93] 0.080
Moment comparison
Treatment end - Diagnosis 0.49 0.13 [0.23; 0.74] < 0.001
2 years post therapy - Diagnosis 0.69 0.15 [0.39; 0.99] < 0.001
Current - Diagnosis 0.34 0.15 [0.03; 0.65] 0.032
Age at diagnosis -0.10 0.03 [-0.16; -0.04] 0.001
Age at diagnosis centered at 7.5 years.
BMI Body mass index, ALL Acute lymphocytic leukemia, CRT Cranial radiotherapy, SE Standard error, CI Confidence interval.
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including exposure to CRT, considering that survivors
exposed and not exposed to CRT presented similar BMI
Z score at the initiation of ALL treatment and in the
first 2 years after therapy withdrawal, which is known as
the critical period of the adiposity rebound.
The late effects of CRT have become an important
issue in the follow-up of patients who were treated for
cancer in childhood, and excessive fat accumulation has
been a frequent adverse effect, especially for ALL pa-
tients during treatment, in the rebound of adiposity, and
many years after therapy withdrawal [2-4,6]. However,
the mechanisms by which CRT affects energy regulato-
ry pathways and the hypothalamic metabolic circuits
resulting in body fat alterations are not clear. A hypo-
thalamic insult, such as CRT or intrathecal methotrex-
ate, may lead to alterations in satiety centers or increase
parasympathetic tone. Moreover, growth hormone defi-
ciency, which may occur in ALL patients subjected to
CRT, may have an impact on body composition and lipid
levels. These alterations could lead to body fatness and
metabolic derangements, both of which are factors that
are suggested to contribute to features of the metabolic
syndrome in this group of patients [2,4-6,11-14]. How-




Moment n Mean SE 95%CI n Mean SE 95%CI n Mean SE 95%CI
Diagnosis 53 -0.25 0.18 [-0.61 ; 0.11] 29 -0.56 0.24 [-1.04 ; -0.08] 24 0.06 0.26 [-0.47 ; 0.58]
Treatment end 55 0.24 0.13 [-0.02 ; 0.49] 30 0.03 0.17 [-0.31 ; 0.38] 25 0.44 0.19 [0.06 ; 0.82]
2 years post therapy 56 0.44 0.12 [0.19 ; 0.68] 31 0.25 0.16 [-0.08 ; 0.58] 25 0.63 0.18 [0.26 ; 0.99]
Current 56 0.09 0.15 [-0.21 ; 0.39] 31 -0.09 0.20 [-0.49 ; 0.31] 25 0.27 0.22 [-0.18 ; 0.72]
Age at ALL diagnosis centered at 7.5 years
Figure 1 BMI Z score along different moments of ALL therapy. BMI Z score in 56 survivors of childhood ALL, according to the exposure to
CRT, along different moments of therapy. BMI: Body mass index; ALL: Acute lymphocytic leukemia; CRT: Cranial radiotherapy; SE: Standard error;
CI: Confidence interval.
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therapy, such as individual host and genetic characteris-
tics, may moderate and influence adiposity and meta-
bolic derangements in this group of patients [3,7,8].
In the current study, FMI was selected to assess body
fat and was elevated by CRT treatment, which concurs
with previous data [11,12]. Abdominal CT scans were
further performed to assess fat deposits directly and spe-
cifically. Prior to the Janiszewiski et al. study [11], vis-
ceral adiposity evaluations were indirect, inconsistent
and limited, and they were performed using circumfer-
ence measurements and DXA (trunk fat) [12,36]. Expos-
ure to CRT increased abdominal fat in patients in this
study, which concurred in previous reports [11].
There was no association between CRT and other clin-
ically used anthropometric indexes such as BMI, WC or
waist-to-hip ratio. By analysing the retrospective BMI Z
score data at different moments of ALL therapy, it was
evident that ALL subjects increased their BMI during
treatment, particularly at the rebound of adiposity, even
though it was not affected by CRT, contrary to the
Childhood Cancer Survivor Study data [3], which is the
largest obesity study of the United States cancer survivor
population. The Childhood Cancer Survivor Study
showed that the influence of CRT on the increase in
BMI in ALL survivors was more evident in females ex-
posed to CRT. To date, few patients in the present study
were currently considered obese by means of BMI ana-
lysis (2 males, 8.3% of the ALL male subjects versus
13.8% from the Childhood Cancer Survivor Study at the
age of 18-24 years) [3], which is in accord with other
studies that have not found obesity in survivors of ALL
by employing measures of BMI, despite the rebound of
adiposity [8,9,37].
There may be several reasons for this lack of associ-
ation between CRT and BMI in the present study: 1- a
low number of subjects fulfilled the criteria for obesity
based on BMI and 2- this measure is too broad and not
specific enough for adipose tissue amounts. Neverthe-
less, BMI is a valuable clinical tool, but it does not evalu-
ate abdominal fat deposits, which have critical clinical
consequences, especially among this population, because
of its implications in the risk of developing premature
cardiovascular disease [12-14,38]. Additional clinical
tools have been used to assess fat distribution, including
circumferences and their relations. These indexes are
used in epidemiological studies, as well as in the clinical
setting, but they also have several limitations that make
them inferior to the direct measurement of adipose tis-
sue mass [28,30].
Concerning the lipid panel for the evaluation of car-
diovascular disease risk factors, the results of this study
showed increased levels of LDL cholesterol in the CRT
group, to date with no clinical relevance, which is in
accordance with other reports [11,12,36]. Nonetheless,
HDL cholesterol, triglyceride concentrations and insulin
resistance were not altered, and no influence of CRT
was observed, even though these metabolic derange-
ments had been described by various previous studies
[11,12,14,36]. Alterations in body fat and metabolic
panel are clearly multifactorial, being regulated by gen-
der, host characteristics, therapeutic agents (chemother-
apy and exposure to CRT) and hormonal deficiencies.
Although it was not within the aim of this study, factors
other than CRT could have influenced body fatness and
metabolic profile in this population, such as the young
age, shorter post treatment interval, overprotection due
to illness, intense parental care giving, and medical sup-
port [5,6,8].
This study population included 56 survivors of ALL
from a single institution, and none of the ALL subjects
currently assessed was within the period of the adiposity
rebound or presented any other condition that would
modify body fat or the metabolic state. In addition, sig-
nificant differences in BMI Z scores were not present
before ALL diagnosis or treatment. Patients subjected to
CRT were older than those not exposed as they may
have underwent preceding GBTLI protocols (GBTLI-85
and -93) [15,16], which indicated prophylactic CRT to
all patients at risk for relapse; however, this difference
regarding age was not clinically relevant. Concerning
CRT and its detrimental effects, the latest GBTLI-99
protocol has reserved therapeutic CRT to patients with
central nervous system involvement so that patients
treated for ALL are not exposed to prophylactic CRT
[16]. The effects of drugs (e.g., intrathecal methotrexate)
and ALL itself on the central nervous system and the
implications for fatness are issues that require further
study [2,39].
Conclusions
Overall, CRT contributed to an increase in body fatness
and modification of fat distribution and lipid panel in
adolescent and young adult survivors of childhood ALL
at a mean chronological age of 18.6 years and 8.5 years
post treatment. Survivors of ALL should be followed
during their lifetime to prevent the risk factors that are
associated with metabolic syndrome and cardiovascular
disease, such as obesity, particularly abdominal obesity.
The present study also showed that simple variables
such as weight and BMI are not sufficient for such a
follow-up. The supplementary indexes, such as fat distri-
bution variables, may better reflect the risk of cardiovas-
cular disease in this group of patients and must be
added. The alterations in adipose tissue deposition
should be assessed by further studies to determine its
true role and pathogenic potential and whether it repre-
sents a disease or a dysfunction in this group of patients.
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